David Berl

David Berl is a highly regarded patent litigator and Co-Chair of the Patent Litigation practice at Williams & Connolly LLP, where he has been a partner since joining the firm in 2002. His practice primarily focuses on high-stakes intellectual property disputes in the biotechnology, pharmaceutical, and energy sectors, with extensive experience in Hatch-Waxman and BPCIA litigation.

In his tracked appearances, Mr. Berl has consistently represented plaintiffs, including his role as Lead Counsel for Astellas Pharma Inc. in a pharmaceutical patent case. Beyond the tracked data, he has served as lead counsel for major corporations, securing favorable verdicts for his clients. Notable successes include leading Genevant in litigation against Moderna concerning COVID-19 vaccine patents, which resulted in a $2.25 billion settlement after Genevant prevailed in IPR appeals. He also achieved a landmark trial victory for Regeneron Pharmaceuticals in BPCIA litigation related to its Eylea® product, confirming patent validity and infringement and securing permanent and preliminary injunctions.

Mr. Berl possesses significant experience in proceedings before the Patent Trial and Appeal Board (PTAB) and the U.S. Court of Appeals for the Federal Circuit. He successfully argued before the PTAB that patents asserted against Petroleum GeoServices were invalid, overturning a prior district court judgment. His appellate experience also includes prevailing in multiple Federal Circuit appeals concerning IPR challenges.

He earned his J.D. from Stanford Law School in 2000, where he was a member of the Order of the Coif, and holds an undergraduate degree in biology from the Massachusetts Institute of Technology (MIT) received in 1997. He was admitted to legal practice in 2000.